Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CDKN2A loss |
| Therapy | Palbociclib |
| Indication/Tumor Type | head and neck cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CDKN2A loss | head and neck cancer | sensitive | Palbociclib | Phase II | Actionable | In a Phase II trial (TAPUR), Ibrance (palbociclib) treatment led to a disease control rate (DCR) of 40% (11/28), objective response rate (ORR) of 4% (1/28, 1 partial response), median progression-free survival (mPFS) of 11 weeks and median overall survival (mOS) of 42 weeks in patients with heavily pretreated head and neck cancer harboring CDKN2A alterations, and a DCR of 13% (5/40), ORR of 5% (2/40), mPFS of 8 weeks, and mOS of 26 weeks in patients with advanced solid tumors (PMID: 39413339; NCT02693535). | 39413339 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39413339) | Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. | Full reference... |